Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FibroScint
- Development stage
- Unknown
- Lead developer
- NorthStar Medical Radioisotopes
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
FibroScint (Tc-99m F4A) is a diagnostic nuclear imaging radiopharmaceutical being developed by Capella Imaging for the detection of cardiovascular thrombi. The agent consists of a small peptide (F4A) that specifically targets and binds to fibrin, a key structural component of blood clots, labeled with the radioisotope technetium-99m (Tc-99m). This allows for the visualization of active thrombi using Single Photon Emission Computed Tomography (SPECT) imaging. Originally invented by researchers at the Washington University School of Medicine, FibroScint is intended to address unmet diagnostic needs in conditions such as left ventricular assist device (LVAD) thrombosis, deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). The drug received FDA Investigational New Drug (IND) clearance in August 2024 and is currently in early-stage clinical development.
- Brand names
- FibroScint
- Other names
- technetium-99m F4Atechnetium99m F4Atechnetium 99m F4ATc-99m-labeled fibrin-targeting peptideTc99m-labeled fibrin-targeting peptideTc 99m-labeled fibrin-targeting peptide
02
Targets
Fibrin (Factor Ia)
Beyond the preview
Go deeper on FibroScint.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FibroScint.